Comparing the current results to its competitors, Tradeup Acquisition reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 10 %, recorded in the same quarter.
Tradeup Acquisition's Comment on Competition and Industry Peers
Estrella operates in the biotechnology and pharmaceutical industry, specializing in cell therapy and immunotherapy for cancer treatment. The company competes with established and emerging biotechnology and pharmaceutical firms, as well as academic and governmental research institutions. Notable competitors in the T-cell therapy sector include Novartis (Kymriah), Kite Pharma, Inc. (Yescarta, Tecartus, KITE-753, KITE-363), Juno Therapeutics Inc. (Bristol Myers Squibb) (Breyanzi), JW Therapeutics (Carteyva/Relma-cel), Allogene Therapeutics (Cema-cel), Mustang Bio (MB-106), Poseida Therapeutics (P-MUC1C-ALLO1, P-CD19CD20-ALLO1), and Autolus Therapeutics PLC (obe-cel, Auto1/2).
February 20, 2025
Evaluating Estrella Immunopharma s Potential Amid Industry Challenges In an ever-evolving biopharmaceutical landscape, Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW), a clinical-stage company pioneering CD19 and CD22-targeted ARTEMIS T-cell therapies for cancer and autoimmune diseases, has recently caught investors eyes. D. Boral Capital LLC, a reputable investment bank, recently initiated coverage on Estrella, assigning it a Buy rating with a 12-month price target of $16.00. This optimistic outlook is based on Estrella s novel approach towards tackling critical health issues and potential to make significant strides in immunotherapy.Estrella s ARTEMIS T-cell therapies represent a promising advancement i...
September 27, 2024
In a groundbreaking advancement in the realm of cancer and autoimmune disease therapies, Estrella Immunopharma, Inc. (NASDAQ: ESLA, ESLAW) has reported a significant milestone in its clinical experimentation. The biopharmaceutical company, focused on developing innovative CD19 and CD22-targeted ARTEMIS T-cell therapies, has celebrated the success of the first patient enrolled in its STARLIGHT-1 Phase I/II clinical trial, achieving a complete response (CR) just one month post-infusion of EB103 CD19-Redirected ARTEMIS T Cells.This remarkable outcome highlights the potential of the ARTEMIS platform, which leverages the unique capabilities of redirected T-cells to precisely target and eliminate neoplastic cells ...
Turnstone Biologics Corp is a biotechnology company that focuses on developing innovative cancer treatments. Their business model includes leveraging their proprietary vaccinia virus-based platform to engineer oncolytic viral immunotherapies. These therapies are designed to selectively target and destroy cancer cells while also activating the patient's immune system to generate a lasting anti-tumor response.
Armata Pharmaceuticals Inc operates on a research and development business model focused on discovering and developing bacteriophage-based therapies to combat antibiotic-resistant infections. They utilize their proprietary phage technology platform to create novel pharmaceutical products targeting various bacterial diseases.
Apogee Therapeutics Inc is a biopharmaceutical company that focuses on developing innovative therapies for various medical conditions. Their business model revolves around conducting extensive research to identify potential drug candidates, and then advancing them through preclinical and clinical trials to secure regulatory approvals. By licensing or partnering with larger pharmaceutical companies, Apogee Therapeutics aims to bring these drugs to market and improve patient outcomes.
Alector Inc's business model focuses on developing novel therapeutics for neurodegenerative diseases using its proprietary platform and partnering with pharmaceutical companies for clinical trials and commercialization.
Sources:
Tradeup Acquisition Corp’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Tradeup Acquisition Corp versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
